Добірка наукової літератури з теми "NSCLP"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "NSCLP".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "NSCLP"
Machado, Renato Assis, Lilianny Querino Rocha de Oliveira, Ana Lúcia Carrinho Ayroza Rangel, Silvia Regina de Almeida Reis, Rafaela Scariot, Daniella Reis Barbosa Martelli, Hercílio Martelli-Júnior, and Ricardo D. Coletta. "Brazilian Multiethnic Association Study of Genetic Variant Interactions among FOS, CASP8, MMP2 and CRISPLD2 in the Risk of Nonsyndromic Cleft Lip with or without Cleft Palate." Dentistry Journal 11, no. 1 (December 26, 2022): 7. http://dx.doi.org/10.3390/dj11010007.
Повний текст джерелаSavitha, Sathyaprasad, S. M. Sharma, Shetty Veena, and R. Rekha. "Single nucleotide polymorphism of bone morphogenetic protein 4 gene: A risk factor of non-syndromic cleft lip with or without palate." Indian Journal of Plastic Surgery 48, no. 02 (May 2015): 159–64. http://dx.doi.org/10.4103/0970-0358.163053.
Повний текст джерелаGoldsberry, Grant, Dan O'Leary, Rich Hichwa, and Peg Nopoulos. "Functional Abnormalities in the Neural Circuitry of Reading in Men with Nonsyndromic Clefts of the Lip or Palate." Cleft Palate-Craniofacial Journal 43, no. 6 (November 2006): 683–90. http://dx.doi.org/10.1597/05-043.
Повний текст джерелаXavier, D. L., Y. A. Arif, R. V. Murali, S. Kishore Kumar, S. Vipin Kumar, R. Tamang, K. Thangaraj, and L. V. K. Bhaskar. "Analysis of Microsatellite Polymorphisms in South Indian Patients with Non Syndromic Cleft Lip and Palate." Balkan Journal of Medical Genetics 16, no. 1 (June 1, 2013): 49–54. http://dx.doi.org/10.2478/bjmg-2013-0017.
Повний текст джерелаAndrews-Casal, Melanie, Dennis Johnston, Jack Fletcher, John B. Mulliken, Samuel Stal, and Jacqueline T. Hecht. "Cleft Lip with or without Cleft Palate: Effect of Family History on Reproductive Planning, Surgical Timing, and Parental Stress." Cleft Palate-Craniofacial Journal 35, no. 1 (January 1998): 52–57. http://dx.doi.org/10.1597/1545-1569_1998_035_0052_clwowc_2.3.co_2.
Повний текст джерелаOtero, Liliana, Luis Bermudez, Karina Lizarraga, Irene Tangco, Rocelyn Gannaban, and Daniel Meles. "A Comparative Study of Facial Asymmetry in Philippine, Colombian, and Ethiopian Families with Nonsyndromic Cleft Lip Palate." Plastic Surgery International 2012 (October 24, 2012): 1–6. http://dx.doi.org/10.1155/2012/580769.
Повний текст джерелаKhan, Mahamad Irfanulla, Prashanth CS, and Narasimhamurty Srinath. "Role of PAX7 Gene rs766325 and rs4920520 Polymorphisms in the Etiology of Non-syndromic Cleft Lip and Palate: A Genetic Study." Global Medical Genetics 09, no. 03 (July 15, 2022): 208–11. http://dx.doi.org/10.1055/s-0042-1748531.
Повний текст джерелаAlam, Mohammad Khursheed, Ahmed Ali Alfawzan, Fatema Akhter, Haytham Jamil Alswairki, and Prabhat Kumar Chaudhari. "Evaluation of Lip Morphology and Nasolabial Angle in Non-Syndromic Cleft Lip and/Palate and Non-Cleft Individuals." Applied Sciences 12, no. 1 (December 30, 2021): 357. http://dx.doi.org/10.3390/app12010357.
Повний текст джерелаLiberton, Denise K., Payal Verma, Konstantinia Almpani, Peter W. Fung, Rashmi Mishra, Snehlata Oberoi, Figen Ç. Şenel, et al. "Craniofacial Analysis May Indicate Co-Occurrence of Skeletal Malocclusions and Associated Risks in Development of Cleft Lip and Palate." Journal of Developmental Biology 8, no. 1 (January 28, 2020): 2. http://dx.doi.org/10.3390/jdb8010002.
Повний текст джерелаNeela, Praveen Kumar, Gosla Srinivas Reddy, Akhter Husain, Vasavi Mohan, Sravya Thumoju, and Rajeshwari BV. "Association of Single Nucleotide Polymorphisms on Locus 18q21.1 in the Etiology of Nonsyndromic Cleft Lip Palate (NSCLP) in Indian Multiplex Families." Global Medical Genetics 08, no. 01 (February 19, 2021): 024–31. http://dx.doi.org/10.1055/s-0041-1723087.
Повний текст джерелаДисертації з теми "NSCLP"
Bianco, Anna Monica Rosaria. "Characterization of novel genes insolved in non syndromic cleft lip with or with out cleft palate (NSCLP)." Doctoral thesis, Università degli studi di Trieste, 2010. http://hdl.handle.net/10077/3735.
Повний текст джерелаNon-syndromic cleft lip with or without cleft palate (NSCLP) is one of the most common birth defect. Genetic studies on human populations have identified numerous predisposing factors, as MYH9 and JARID2, whose role during palatogenesis remains obscure. In order to improve our knowledge on pathogenetic mechanisms, we carried out expression studies during mouse palate development using RNA in situ hybridization. As reference genes (Tgfb3, Irf6, Pvrl1, Foxe1 and Tp63) known to be required for correct palate formation, Jarid2 and Myh9 are expressed in the epithelial cells of the palatine processes before and at the time of contact. Then, this signal decreases and eventually disappears concomitantly with the degradation of the medial epithelial cells. Consistent with these observations, RT-PCR carried out on dissected palatal shelves detected products of Myh9 and Jarid2 from embryonic day E14.0 to E15.0 with a pick at E14.5, the stage when shelves appose in the midline. Taken together, these expression studies strongly support the association studies that designate these genes as predisposing factors for NSCLP. In multifactorial diseases as NSCLP once genetic studies demonstrate association, a major challenge is to identify mutations. In this regard, we started analyzing two in linkage disequilibrium SNPs (rs3752462 of MYH9 and rs2076056 of JARID2) that could be involved in defective splicing mechanisms, as hypothesized on the basis of their localization within splice sites. Using a hybrid minigene assay, however, we demonstrated that none of the allelic variants lead to any aberrant products at least in HeLa cells, the model used for this study. Moreover, we investigated whether alternative splicing events of the Myh9 gene detected in cochlea and brain (Li et al., 2008) could also be found in other tissues and palate. A small insertion of 12 bp between exon 4 and 5 (loop1) due to an alternative splicing was detected in all adult tissues analyzed. The same insertion was not detected in embryonic tissues, such as palatal samples at different stages of development, and brain. These results suggest that the genomic region of loop1 should be investigated in all risk haplotypes to search for pathogenetic variants. In conclusion, further investigations should be planned to explore the role of MYH9 and JARID2 in orofacial development in order to dissect signaling pathways during palate formation and identify the causative variants contributing to NSCLP.
XXII Ciclo
1973
Krüger, Marcus. "Molekulare und funktionale Charakterisierung der neuronalen bHLH Transkritptionsfaktoren NSCL-1 und NSCL-2." [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=969337183.
Повний текст джерелаPegoraro, Ilan Emanuel Moreira. "NSCL in the ETSI M2M platform." Master's thesis, Universidade de Aveiro, 2014. http://hdl.handle.net/10773/14704.
Повний текст джерелаThe evolution of every day gadgets into smart-devices able to react to their surrounding environment is enabling the development of novel applications aiming revolutionize the industry related to this technology. Currently much attention has been given to standardizing IoT and M2M in order to build an interoperable foundation that will enable the growth of the future Internet, where devices will communicate without, or at least minimizing, human intervention. In this dissertation is presented in first place issues such as: heterogeneity, scalability, addressing and the first approach taken by the ETSI M2M standard. Subsequently, is presented the ETSI M2M vision and high-level architecture together with current work in this area. Finally an implementation of the network middleware is going to be presented along with further testing.
A evolução dos dispositivos do dia a dia em dispositivos inteligentes capazes de reagir ao ambiente que os rodeia está a permitir a criação de novas aplicações que visam revolucionar a industria. Atualmente tem-se dado muita atenção a estandardização da Internet das Coisas e comunicações máquinaa- máquina, com o objetivo de construir uma fundação interoperável que permitirá o crescimento futuro da Internet, onde os dispositivos irão comunicar sem, ou com mínima, intervenção humana. Nesta dissertação é apresentado em primeiro lugar requisitos como heterogeneidade, escalabilidade, endereçamento e a primeira abordagem feita pelo standard M2M do ETSI. Consequentemente, é a apresentada a visão e a arquitetura e o trabalho realizado nesta área. Por fim é apresentada a implementação da componente de rede realizada nesta dissertação juntamente com os respetivos testes.
Chater, Emily. "Novel therapeutic targets in NSCLC resistance to Erlotinib." Thesis, Imperial College London, 2017. http://hdl.handle.net/10044/1/50699.
Повний текст джерелаHolgersson, Georg. "Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC)." Doctoral thesis, Uppsala universitet, Experimentell och klinisk onkologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-327925.
Повний текст джерелаStamatkin, Christopher W. "PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) AS A THERAPEUTIC TARGET IN NSCLC." UKnowledge, 2014. http://uknowledge.uky.edu/pharmacy_etds/58.
Повний текст джерелаChatterjee, Saradiya. "Role of TLR7 in non-small cell lung carcinona (NSCLC)." Paris 6, 2013. http://www.theses.fr/2013PA066063.
Повний текст джерелаLung cancer accounts for over 1 million deaths per year with a 5-year survival of 8-12%. Stimulation of TLRs by the natural ligands like the PAMPs and DAMPs results in a proinflammatory signaling cascade. We have shown that stimulation of lung cancer cell lines with TLR7 agonist lead to tumor cell survival and chemoresistance in vitro. We studied the effect of TLR7 agonists on A549 and LL/2 cells injected in NOD/SCID and C57BL/6 mice either treated or not with cisplatin. Loxoribine has a pro-tumoral effect on A549 cells and induces chemoresistance in NOD/SCID mice. Blockade of TLR7 with IRS661 reversed the pro-tumoral effect of TLR7 agonist on A549 cells. CL264 was also found to have a pro-tumoral effect on LL/2 cells and induced chemoresistance in NOD/SCID mice. On the other hand CL264 at lower concentration induces an anti-tumoral effect on LL/2 cells while at a higher concentration demonstrated a pro-tumoral effect in C57BL/6 mice. We also demonstrated an overall bad prognostic value for higher expression of TLR7 by tumoral cells among NSCLC patients treated and not treated with neoadjuvant chemotherapy. These results suggest a pro- tumoral role and induction of chemoresistance by TLR7 in NSCLC patients. Use of TLR7 agonist as therapeutic option is recommended based on the TLR7 expression level for individual NSCLC patients. TLR7 antagonist holds promise for treatment of NSCLC in future
Recondo, Gonzalo. "Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS248/document.
Повний текст джерелаThe molecular study and classification of lung adenocarcinomas has led to the development of selective targeted therapies aiming to improve disease control and survival in patients. The anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor from the insulin tyrosine kinase receptor family, with a physiologic role in neural development. Gene rearrangements involving the ALK kinase domain occur in ~3-6% of patients with lung adenocarcinoma. The fusion protein dimerizes leading to transactivation of the ALK kinase domain in a ligand-independent and constitutive manner. Lorlatinib is a third generation ALK inhibitor with high potency and selectivity for this kinase in vitro and in vivo, and elevated penetrance in the central nervous system. Lorlatinib can overcome resistance mediated by over 16 secondary kinase domain mutations occurring in 13 residues upon progression to first - and second - generation ALK TKI. In addition, treatment with lorlatinib is effective for patients who have been previously treated with a first and a second generation or a second generation ALK TKI upfront and is currently approved for this indication. The full spectrum of biological mechanisms driving lorlatinib resistance in patients remains to be elucidated. It has been recently reported that the sequential acquisition of two or more mutations in the kinase domain, also referred as compound mutations, is responsible for disease progression in about 35% of patients treated with lorlatinib, mainly by impairing its binding to the ALK kinase domain. However, the effect of these compound mutations on the sensitivity to the repertoire of ALK inhibitors can vary, and other resistance mechanisms occurring in most patients are unknown. My PhD thesis aimed at exploring resistance to lorlatinib in patients with ALK-rearranged lung cancer through spatial and temporal tumor biopsies and development of patient-derived models. Within the institutional MATCH-R study (NCT02517892), we performed high-throughput whole exome, RNA and targeted next-generation sequencing, together with plasma sequencing to identify putative genomic and bypass mechanisms of resistance. We developed patient-derived cell lines and characterized novel mechanisms of resistance and personalized treatment strategies in vitro and in vivo. We characterized three mechanisms of resistance in four patients with paired biopsies. We studied the induction of epithelial-mesenchymal transition (EMT) by SRC activation in a patient-derived cell line exposed to lorlatinib. Mesenchymal cells were sensitive to combined SRC and ALK co-inhibition, showing that even in the presence of an aggressive and challenging phenotype, combination strategies can overcome ALK resistance. We identified two novel ALK kinase domain compound mutations, F1174L/G1202R, C1156Y/G1269A, occurring in two patients treated with lorlatinib. We developed Ba/F3 cell models harboring single and compound mutations to study the differential effect of these mutations on lorlatinib resistance. Finally, we characterized a novel mechanism of resistance caused by NF2 loss of function at the time of lorlatinib progression through the development of patients derived PDX and cell lines, and in vitro validation of NF2 knock-out with CRISPR/CAS9 gene editing. Downstream activation of mTOR was found to drive lorlatinib resistance by NF2 loss of function and was overcome by providing treatment with mTOR inhibitors.This study shows that mechanisms of resistance to lorlatinib are more diverse and complex than anticipated. Our findings also emphasize how longitudinal studies of tumor dynamics allow deciphering TKI resistance and identifying reversing strategies
Baghai, Tabassom. "ATF3 as a Key Regulator of Cisplatin Cytotoxicity: Combining ATF3 Inducing Agents Enhances Cisplatin Activity in NSCLC." Thesis, Université d'Ottawa / University of Ottawa, 2018. http://hdl.handle.net/10393/37963.
Повний текст джерелаDaskalos, Alexandros. "Deregulation of DNA methylation aand retrotransposon reactivation in NSCL." Thesis, University of Liverpool, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.539561.
Повний текст джерелаКниги з теми "NSCLP"
U.S. Army Chemical Materiel Destruction Agency., ed. Non-Stockpile Chemical Materiel Program: NSCMP. [Aberdeen Proving Ground, MD: U.S. Army Chemical Materiel Destruction Agency, 1995.
Знайти повний текст джерелаU.S. Army Chemical Materiel Destruction Agency., ed. Non-Stockpile Chemical Materiel Program: NSCMP. [Aberdeen Proving Ground, MD: U.S. Army Chemical Materiel Destruction Agency, 1995.
Знайти повний текст джерелаU.S. Army Chemical Materiel Destruction Agency, ed. Non-Stockpile Chemical Materiel Program: NSCMP. [Aberdeen Proving Ground, MD: U.S. Army Chemical Materiel Destruction Agency, 1995.
Знайти повний текст джерелаU.S. Army Chemical Materiel Destruction Agency, ed. Non-Stockpile Chemical Materiel Program: NSCMP. [Aberdeen Proving Ground, MD: U.S. Army Chemical Materiel Destruction Agency, 1995.
Знайти повний текст джерелаCappuzzo, Federico. Guide to Targeted Therapies: EGFR mutations in NSCLC. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-03059-3.
Повний текст джерелаKim, Ho-jung. array-CGH rŭl iyong han piso sepʻo pʻyeam ŭi chogi chaebal pʻyojija mit chindan mohyŏng kaebal =: Development of early-recurrence detection marker and diagnostic model using array-CGH in NSCLC. [Seoul]: Pogŏn Pokchibu, 2007.
Знайти повний текст джерелаCappuzzo, Federico. Guide to Targeted Therapies : EGFR mutations in NSCLC: EGFR mutations in NSCLC. Adis, 2014.
Знайти повний текст джерелаNon-Stockpile Chemical Materiel Program: NSCMP. [Aberdeen Proving Ground, MD: U.S. Army Chemical Materiel Destruction Agency, 1995.
Знайти повний текст джерелаKrawczyk, Paweł Adam, Qing Zhou, Rafal Dziadziuszko, and Natasha Leighl, eds. Issues and Challenges in NSCLC Immunotherapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-816-0.
Повний текст джерелаNorthumberland Strait Crossing Project (NSCP). [Washington, DC]: Federal Highway Administration, 1996.
Знайти повний текст джерелаЧастини книг з теми "NSCLP"
Shih, Helen. "BRAF in NSCLC." In Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners, 39–49. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16550-5_5.
Повний текст джерелаDu, Lingling, Saiama N. Waqar, and Daniel Morgensztern. "Multimodality Therapy for NSCLC." In Cancer Treatment and Research, 151–63. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40389-2_7.
Повний текст джерелаCappuzzo, Federico. "Therapy options for advanced NSCLC." In Guide to Targeted Therapies: Treatment Resistance in Lung Cancer, 5–25. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20741-4_2.
Повний текст джерелаDoubre, H., C. Le Pechoux, and T. Le Chevalier. "Adjuvant Treatments in Resectable NSCLC." In Malignant Tumors of the Lung, 215–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18698-1_19.
Повний текст джерелаRamírez, J. L., M. F. Salazar, J. Gupta, J. M. Sánchez, M. Taron, M. Sänchez-Ronco, Vicente Alberola, and R. de las Peñas. "Methylation Patterns and Chemosensitivity in NSCLC." In New trends in cancer for the 21st century, 195–209. Dordrecht: Springer Netherlands, 2006. http://dx.doi.org/10.1007/978-1-4020-5133-3_17.
Повний текст джерелаBlackhall, Fiona H. "Strategies in ALK Rearranged NSCLC Patients." In New Therapeutic Strategies in Lung Cancers, 147–56. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06062-0_10.
Повний текст джерелаLouie, Brian E., and Eric Vallières. "Minimally Invasive Surgery for Early NSCLC." In New Therapeutic Strategies in Lung Cancers, 27–32. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06062-0_3.
Повний текст джерелаPisters, Katherine. "Adjuvant and Neoadjuvant Therapy of NSCLC." In Lung Cancer, 139–59. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-524-8_6.
Повний текст джерелаTsao, Anne S., and Jack A. Roth. "Novel and Emerging Agents in NSCLC." In Lung Cancer, 464–78. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch30.
Повний текст джерелаDas, Millie, and Heather Wakelee. "Anti-Angiogenic Agents in Metastatic NSCLC." In Lung Cancer, 527–40. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch34.
Повний текст джерелаТези доповідей конференцій з теми "NSCLP"
Rauthan, Amit, Poonam Patil, Rajashree Aswath, Nitin Yashas, and Gaurav Ningade. "Immunotherapy in Patients with Lung Cancer with Driver Mutations: A Single-Centre Experience." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735365.
Повний текст джерелаBenammar, Sarra, Fatima Mraiche, Jensa Mariam Joseph, and Katerina Gorachinova. "Glucose and Transferrin Liganded PLGA Nanoparticles Internalization in Non-Small Lung Cancer Cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0227.
Повний текст джерелаAlam, Mohammed. "A Decision Analytical Model Investigating Cost-Effectiveness of Erlotinib." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0145.
Повний текст джерелаGelbke, C. Konrad. "FRIB/NSCL Laboratory Update." In Sixth International Conference on Fission and Properties of Neutron-Rich Nuclei (ICFN6). WORLD SCIENTIFIC, 2017. http://dx.doi.org/10.1142/9789813229426_0030.
Повний текст джерелаOllosi, Stephen L., Margaret Soucheray, Jeffrey Becker, Ines Pulido, Annika Dalheim, Fatima Al-Shahrour, Wei Qui, et al. "Abstract 20: Inhibition of mutant EGFR in NSCLC promotes endothelin-1-mediated NSCLC disease progression and angiogenesis." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-20.
Повний текст джерелаShostak, E., R. Liberman, and D. Riker. "Stage I NSCLC: Risk Factors for Recurrence." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1107.
Повний текст джерелаPavicevic, R., and G. Bubanovic. "ERCC1 and RRM1 Expression in Resected NSCLC." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2679.
Повний текст джерелаWu, Yi-Long, and Robert van den Heuvel. "Sugemalimab offers PFS benefits for unresectable NSCLC." In IASLC 2022 World Conference on Lung Cancer, edited by Yi-Long Wu and Rachel Giles. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/675f3ee0.
Повний текст джерелаMolina-Pinelo, Sonia, Gabriel Gutierrez-Pozo, Maria D. Pastor, Marta Hergueta, Gema Moreno-Bueno, Rocio Garcia-Carbonero, Ana BS Nogal, et al. "Abstract 5305: Transcriptionalregulation by microRNAs in NSCLC." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5305.
Повний текст джерелаvan den Heivel, Robert. "Confirmatory mediastinoscopy not needed in resectable NSCLC." In ERS International Congress 2022, edited by Richard Dekhuijzen. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/5e8370b2.
Повний текст джерелаЗвіти організацій з теми "NSCLP"
Dawson, W., J. Boles, and K. Le Galloudec. NSLP-Final Report-Draft2022. Office of Scientific and Technical Information (OSTI), February 2022. http://dx.doi.org/10.2172/1860931.
Повний текст джерелаSherrill, Bradley, and Alexandra Gade. Operation of GRETINA at NSCL. Office of Scientific and Technical Information (OSTI), December 2017. http://dx.doi.org/10.2172/1427801.
Повний текст джерелаYoung, Jamey D., and Young M. Whang. Targeting Redox Homeostasis in LKB1-deficient NSCLC. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada614534.
Повний текст джерелаPeng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao, and Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.
Повний текст джерелаStiemerling, M., H. Tschofenig, C. Aoun, and E. Davies. NAT/Firewall NSIS Signaling Layer Protocol (NSLP). RFC Editor, October 2010. http://dx.doi.org/10.17487/rfc5973.
Повний текст джерелаFreire, Mariana, Diana Martins, Maria Filomena Botelho, and Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.
Повний текст джерелаWinkles, Jeffrey A. GrB-TWEAK: A Potential Novel Biologic for NSCLC Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2015. http://dx.doi.org/10.21236/ada624531.
Повний текст джерелаOuyang, Zhiqiang, Qian Li, Guangrong Zheng, Tengfei Ke, Jun Yang, and Chengde Liao. Radiomics for predicting tumor microenvironment phenotypes in non-small cell lung cance: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0060.
Повний текст джерелаManner, J., G. Karagiannis, and A. McDonald. NSIS Signaling Layer Protocol (NSLP) for Quality-of-Service Signaling. RFC Editor, October 2010. http://dx.doi.org/10.17487/rfc5974.
Повний текст джерелаSeverin, Gregory, E. Paige Abel, and Hannah Clause. Closeout Report: Rare Isotope Generators at the NSCL and FRIB. Office of Scientific and Technical Information (OSTI), January 2022. http://dx.doi.org/10.2172/1837939.
Повний текст джерела